Literature DB >> 28179274

Mouse models of MLL leukemia: recapitulating the human disease.

Thomas A Milne1.   

Abstract

Chromosome translocations involving the mixed lineage leukemia (MLL) gene fuse it in frame with multiple partner genes creating novel fusion proteins (MLL-FPs) that cause aggressive acute leukemias in humans. Animal models of human disease are important for the exploration of underlying disease mechanisms as well as for testing novel therapeutic approaches. Patients carrying MLL-FPs have very few cooperating mutations, making MLL-FP driven leukemias ideal for animal modeling. The fact that the MLL-FP is the main driver mutation has allowed for a wide range of different experimental model systems designed to explore different aspects of MLL-FP leukemogenesis. In addition, MLL-FP driven acute myeloid leukemia (AML) in mice is often used as a general model for AML. This review provides an overview of different MLL-FP mouse model systems and discusses how well they have recapitulated aspects of the human disease as well as highlights the biological insights each model has provided into MLL-FP leukemogenesis. Many promising new drugs fail in the early stages of clinical trials. Lessons learned from past and present MLL-FP models may serve as a paradigm for designing more flexible and dynamic preclinical models for these as well as other acute leukemias.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28179274      PMCID: PMC5399479          DOI: 10.1182/blood-2016-10-691428

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  72 in total

1.  It takes two-to-leukemia: about addictions and requirements.

Authors:  Rolf Marschalek
Journal:  Leuk Res       Date:  2010-11-11       Impact factor: 3.156

2.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors:  Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

3.  Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model.

Authors:  H Tamai; K Miyake; M Takatori; N Miyake; H Yamaguchi; K Dan; T Shimada; K Inokuchi
Journal:  Leukemia       Date:  2011-02-11       Impact factor: 11.528

4.  Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.

Authors:  Lesley F Drynan; Richard Pannell; Alan Forster; Nicole M M Chan; Florencia Cano; Angelika Daser; Terence H Rabbitts
Journal:  EMBO J       Date:  2005-08-11       Impact factor: 11.598

5.  Inter-chromosomal recombination of Mll and Af9 genes mediated by cre-loxP in mouse development.

Authors:  E C Collins; R Pannell; E M Simpson; A Forster; T H Rabbitts
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

6.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

7.  Leukaemia lineage specification caused by cell-specific Mll-Enl translocations.

Authors:  F Cano; L F Drynan; R Pannell; T H Rabbitts
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

8.  Ligand-independent FLT3 activation does not cooperate with MLL-AF4 to immortalize/transform cord blood CD34+ cells.

Authors:  R Montes; V Ayllón; C Prieto; A Bursen; C Prelle; D Romero-Moya; P J Real; O Navarro-Montero; C Chillón; R Marschalek; C Bueno; P Menendez
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

9.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

10.  Mll-AF4 Confers Enhanced Self-Renewal and Lymphoid Potential during a Restricted Window in Development.

Authors:  Neil A Barrett; Camille Malouf; Chrysa Kapeni; Wendi A Bacon; George Giotopoulos; Sten Eirik W Jacobsen; Brian J Huntly; Katrin Ottersbach
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

View more
  45 in total

1.  MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing.

Authors:  Corina Schneidawind; Johan Jeong; Dominik Schneidawind; In-Suk Kim; Jesús Duque-Afonso; Stephen Hon Kit Wong; Masayuki Iwasaki; Erin H Breese; James L Zehnder; Matthew Porteus; Michael L Cleary
Journal:  Blood Adv       Date:  2018-04-24

2.  ENLightening YEATS in antagonizing polycomb repression.

Authors:  Daisuke Nakada
Journal:  Blood       Date:  2018-02-08       Impact factor: 22.113

3.  PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.

Authors:  David J Corrigan; Larry L Luchsinger; Mariana Justino de Almeida; Linda J Williams; Alexandros Strikoudis; Hans-Willem Snoeck
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

Review 4.  Cancer Epigenetics, Tumor Immunity, and Immunotherapy.

Authors:  Jian Cao; Qin Yan
Journal:  Trends Cancer       Date:  2020-03-31

Review 5.  Therapeutic implications of menin inhibition in acute leukemias.

Authors:  Ghayas C Issa; Farhad Ravandi; Courtney D DiNardo; Elias Jabbour; Hagop M Kantarjian; Michael Andreeff
Journal:  Leukemia       Date:  2021-06-15       Impact factor: 11.528

6.  Exploitable metabolic dependencies in MLL-ENL-induced leukemia.

Authors:  Maria-Paz Garcia-Cuellar; Jennifer Lawlor; Martin Böttcher; Dimitrios Mougiakakos; Markus Metzler; Robert K Slany
Journal:  Blood Adv       Date:  2020-08-11

7.  MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia.

Authors:  Hansen J Kosasih; Nadia M Davidson; Stefan Bjelosevic; Emma Morrish; Margs S Brennan; Alicia Oshlack; Ricky W Johnstone; Gabriela Brumatti; Seong L Khaw; Paul G Ekert
Journal:  Blood Adv       Date:  2020-10-13

8.  Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia.

Authors:  Juan Ramón Tejedor; Clara Bueno; Meritxell Vinyoles; Paolo Petazzi; Antonio Agraz-Doblas; Isabel Cobo; Raúl Torres-Ruiz; Gustavo F Bayón; Raúl F Pérez; Sara López-Tamargo; Francisco Gutierrez-Agüera; Pablo Santamarina-Ojeda; Manuel Ramírez-Orellana; Michela Bardini; Giovanni Cazzaniga; Paola Ballerini; Pauline Schneider; Ronald W Stam; Ignacio Varela; Mario F Fraga; Agustín F Fernández; Pablo Menéndez
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

Review 9.  Acute Leukemia in Infants.

Authors:  Azada Ibrahimova; Lauren Pommert; Erin H Breese
Journal:  Curr Oncol Rep       Date:  2021-02-12       Impact factor: 5.075

10.  High-efficiency CRISPR induction of t(9;11) chromosomal translocations and acute leukemias in human blood stem cells.

Authors:  Johan Jeong; Astraea Jager; Pablo Domizi; Mara Pavel-Dinu; Linda Gojenola; Masayuki Iwasaki; Michael C Wei; Feng Pan; James L Zehnder; Matthew H Porteus; Kara L Davis; Michael L Cleary
Journal:  Blood Adv       Date:  2019-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.